📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Module 3 — Control Strategy (OBX-319)

Document ID: M3-CS
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH Q5A-Q5E, Q6B, Q1A(R2), Q11, M4Q

Integrated Control Strategy — OBX-319

The control strategy for OBX-319 links the critical quality attributes to the manufacturing-process controls and the release/stability specifications, consistent with ICH Q8(R2)/Q9/Q10/Q11.

OBX-319 is a humanized IgG1 bispecific monoclonal antibody that simultaneously engages CD19 and CD20 on the B-lineage surface to drive near-complete peripheral B-cell depletion in moderate-to-severe active systemic lupus erythematosus (SLE). The molecule is produced by fed-batch culture of a recombinant Chinese hamster ovary (CHO) cell line and is purified through a platform mammalian-antibody downstream train (Protein A affinity capture followed by orthogonal polishing chromatography and dedicated viral-clearance steps). It is formulated as a high-concentration aqueous solution for subcutaneous administration and presented in a single-use container-closure system. Because the therapeutic and safety profile — dual target engagement, the intended (attenuated) Fc-effector activity, target-mediated drug disposition (TMDD) pharmacokinetics, and immunogenicity/anti-drug-antibody (ADA) potential — is defined by molecular integrity, the control strategy is anchored on assuring correct bispecific assembly, consistent post-translational quality, and a low, well-characterised impurity burden across the product lifecycle.

The Quality Target Product Profile (QTPP) — a sterile, subcutaneously delivered, high-purity bispecific antibody of defined potency against both CD19 and CD20, low aggregate and particulate content commensurate with an injectable biologic, controlled charge and glycan heterogeneity, and demonstrated viral, microbial and endotoxin safety — is the reference point from which critical quality attributes (CQAs) are derived and against which the manufacturing controls and specifications are justified. Attribute criticality is assigned by risk assessment (ICH Q9) that weighs the potential impact of each attribute on safety, efficacy, pharmacokinetics and immunogenicity against the current uncertainty in that impact, drawing on platform prior knowledge for CHO-derived IgG1 antibodies together with molecule-specific data for the bispecific format.

The overall approach combines enhanced (Quality-by-Design, ICH Q11/Q8(R2)) and conventional elements: a characterised, banked cell substrate; controlled raw and starting materials; a defined process with critical process parameters (CPPs) and in-process controls (IPCs) held within qualified ranges; orthogonal purification that both delivers the intended product and clears process- and product-related impurities and adventitious agents; and drug-substance and drug-product specifications populated with validated, stability-indicating analytical procedures. No single test assures quality; assurance is distributed across the manufacturing process, the analytical control system, and the release and stability specifications, and is maintained under the pharmaceutical quality system (ICH Q10) with lifecycle change management supported by comparability (ICH Q5E).

Critical quality attributes

• Dual, arm-specific target binding & potency
• Correct bispecific chain pairing / assembly
• Aggregation (HMW) & fragmentation
• N-glycosylation profile / effector attenuation
• Charge variants (deamidation/isomerisation)
• Host-cell impurities, viral & endotoxin safety

Each attribute above is retained as a CQA on the basis of a documented impact-versus-uncertainty assessment; product-quality attributes judged not to affect the QTPP are managed as routine controls rather than release-critical parameters. The bispecific format makes correct assembly and dual functionality the defining CQAs for OBX-319, over and above the aggregation, glycosylation, charge-variant and impurity attributes shared with conventional monoclonal antibodies. The table below summarises, for each CQA class, why it is critical and the principal points of control; acceptance criteria are set in the drug-substance and drug-product specifications and justified by clinical, nonclinical and stability experience together with platform knowledge (ICH Q6B).

CQA class	Representative attributes	Why critical (impact on QTPP)	Principal controls
Dual, arm-specific binding & potency	CD19-arm binding, CD20-arm binding, cell-based B-cell-depletion / effector potency, dual identity	Governs the intended mechanism (co-engagement of CD19 and CD20 to deplete B cells); loss of either arm changes efficacy and safety	Two-arm binding assays (e.g. SPR/ELISA), a mechanism-reflective cell-based bioassay, orthogonal identity confirming both specificities; reference standard qualification
Correct bispecific chain pairing / assembly	Intended heterodimer content; mispaired/product-related species (homodimers, half-antibodies, light-chain mispairing, knob-knob / hole-hole species)	Mispaired and half-molecule species can be monospecific or non-functional, may shift potency, PK and immunogenicity	Heterodimerisation design and clone selection; orthogonal polishing (e.g. ion-exchange, mixed-mode, hydrophobic-interaction) to resolve mispaired species; intact/subunit mass spectrometry and high-resolution size/charge methods as characterisation and control
Aggregation (HMW) & fragmentation	High-molecular-weight species (dimer/oligomer), subvisible and visible particulates, low-molecular-weight fragments (clips)	Aggregates and particulates are a primary immunogenicity risk driver — heightened for a high-concentration subcutaneous product — and fragmentation reduces functional antibody	SEC (with orthogonal AUC/light-scattering characterisation), subvisible-particle testing (compendial light-obscuration and micro-flow imaging), non-reduced CE-SDS; formulation, surfactant and process/hold-time controls; container-closure and shipping controls
N-glycosylation profile / effector attenuation	Afucosylation, high-mannose, galactosylation, sialylation; C-terminal/other Fc features influencing effector function	The Fc N-glycan profile modulates Fc-effector activity (ADCC/CDC/ADCP) and clearance; it must remain within ranges that preserve the molecule's intended, attenuated effector profile and consistent depletion potency	Cell-culture control (media, feeds, temperature, pH, duration) as the primary lever; released-glycan / glycopeptide mapping; potency-linked monitoring; specification limits on key glycan species
Charge variants (deamidation / isomerisation)	Acidic and basic variants; Asn deamidation, Asp isomerisation, N-terminal pyroglutamate, C-terminal lysine, oxidation at CDR/Fc hotspots	Modifications at complementarity-determining-region hotspots can alter binding of either arm; charge heterogeneity is a stability-indicating attribute	Charge-based methods (cIEF/icIEF, ion-exchange), peptide mapping for site-specific identification; cell-culture, purification, formulation and storage controls; forced-degradation understanding of hotspots
Host-cell impurities, viral & endotoxin safety	Host-cell protein (HCP), residual CHO DNA, Protein A / affinity-ligand leachate, bioburden, endotoxin, adventitious and endogenous (retrovirus-like) agents	Process-related impurities carry immunogenicity, safety and, for residual DNA, theoretical oncogenicity/infectivity concerns; microbial and viral safety are prerequisites for an injectable biologic	Protein A capture plus orthogonal polishing for HCP/DNA/leachate reduction; validated viral clearance (low-pH inactivation and virus-retentive nanofiltration) per ICH Q5A(R2); HCP immunoassay, residual-DNA qPCR, leachate assay; bioburden/endotoxin IPCs and sterile-filtration controls

Control approach

Each CQA is controlled by a combination of raw-material controls, in-process controls and process parameters (recombinant Chinese hamster ovary (CHO) mammalian cell culture (fed-batch)), and specification testing (drug substance 3.2.S.4, drug product 3.2.P.5). Analytical methods are validated per ICH Q2(R2).

Cell substrate and raw materials. The master and working cell banks are established, characterised and tested for identity, viability, genetic stability and freedom from adventitious agents in accordance with ICH Q5A-Q5E and Q5D, and end-of-production cells are assessed to confirm control of the expression construct over the intended production age. Media, feeds, process chemicals and chromatography resins are qualified against material specifications; animal-origin-free sourcing and supplier controls are applied to minimise adventitious-agent risk, and critical raw materials are linked to the CQAs they influence (for example, feed and media components that affect the glycosylation profile).

Upstream (cell culture). Fed-batch production is operated within qualified ranges for the parameters that most influence product quality and yield — inoculum and seed-train control, bioreactor temperature, pH, dissolved oxygen, feed strategy and culture duration — with CPPs distinguished from key and non-critical parameters through process characterisation. In-process controls monitor viable-cell density, viability, titre, bioburden and, where appropriate, glycan-relevant indicators, so that the harvest presented to purification is consistent with respect to the assembly, glycosylation and impurity attributes established downstream.

Downstream (purification and viral clearance). Protein A affinity capture provides the primary reduction of HCP and CHO DNA and defines the antibody pool; subsequent orthogonal polishing chromatography (ion-exchange, mixed-mode and/or hydrophobic-interaction, as defined by the process) removes aggregates, fragments, charge variants and — critically for the bispecific format — mispaired and half-molecule product-related species, while further reducing HCP, residual DNA and affinity-ligand leachate. Dedicated viral-clearance operations, including low-pH viral inactivation and virus-retentive nanofiltration, are validated for robust clearance of enveloped and non-enveloped model viruses and of the endogenous retrovirus-like particles inherent to CHO substrates, per ICH Q5A(R2). Chromatographic performance, pool criteria, and bioburden/endotoxin are monitored as in-process controls, and processing and hold times are qualified to bound aggregation, fragmentation and microbial risk.

Drug substance and drug product specifications. Release and stability specifications for the drug substance (3.2.S.4) and drug product (3.2.P.5) are structured per ICH Q6B and include: appearance and content (protein concentration); dual identity confirming both the CD19 and CD20 specificities; potency by target-binding and cell-based methods reflecting the depletion mechanism; purity/impurity by size (SEC, CE-SDS reduced and non-reduced) and charge (icIEF/ion-exchange); product-related species including aggregate and mispaired-species control; the glycosylation profile; process-related impurities (HCP, residual CHO DNA, leachate); subvisible and visible particulates; and safety attributes (sterility, endotoxin, container-closure integrity). Impurities are qualified under the ICH Q6B biotechnology paradigm rather than the small-molecule Q3A/Q3B approach, with elemental impurities addressed per ICH Q3D and residual solvents per ICH Q3C where applicable. Acceptance criteria are set from the demonstrated capability of the process and from clinical and nonclinical exposure, and are supported by a qualified reference standard maintained under a two-tiered (primary/working) programme.

Analytical control, stability and lifecycle. Analytical procedures are validated for their intended use per ICH Q2(R2), with orthogonal, higher-resolution methods (for example, intact and subunit mass spectrometry, peptide mapping, and biophysical characterisation) supporting extended characterisation and comparability rather than routine release. Stability is evaluated under ICH Q1A(R2) and the biotech-specific ICH Q5C, using stability-indicating methods and forced-degradation studies to establish shelf life and to confirm control of the degradation-prone attributes (aggregation, fragmentation, charge and glycan changes); the formulation, surfactant level and container-closure system are selected to control aggregation, particulates and, given the subcutaneous high-concentration presentation, to maintain deliverability. Post-approval changes are managed under the pharmaceutical quality system (ICH Q10) with comparability assessments (ICH Q5E) to confirm that quality, and hence the established safety and efficacy, is maintained.

Governing guidelines: ICH Q5A-Q5E, Q6B, Q1A(R2), Q11, M4Q.